7 completed. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
Follow PSA Progression: new trials by email Literature Review of PSA Progression trials Research Report on PSA Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer Gallium Ga 68 DOTA-NeoBOMB1, Gallium Ga 68 PSMA-R2 - Prostate Adenocarcinoma, PSA Progression | Phase 2 | Completed | Andrei Iagaru | 27 | 2020-12-15 | 2024-01-30 |
| Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer Apalutamide, Stereotactic Body Radiation Therapy - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | University of California, San Francisco | 26 | 2019-12-17 | 2026-01-21 |
| Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis, Pembrolizumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 15 | 2018-06-07 | 2023-05-03 |
| 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Completed | Jonsson Comprehensive Cancer Center | 937 | 2018-04-02 | 2021-09-30 |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer ESK981 - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 13 | 2018-03-08 | 2023-07-14 |
| Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway Carboplatin, Docetaxel, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | University of Washington | 14 | 2016-01-26 | 2022-11-17 |
| Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide Enzalutamide, Laboratory Biomarker Analysis, Pembrolizumab - Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer | Phase 2 | Completed | OHSU Knight Cancer Institute | 58 | 2014-11-18 | 2026-10-28 |
Genital Diseases (5) · Genital Diseases, Male (5) · Genital Neoplasms, Male (5) · Male Urogenital Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Prostatic Diseases (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5)
pembrolizumab (2) · 68Ga-DKFZ-PSMA-11 (1) · Carboplatin (1) · Docetaxel (1) · Magnetic Resonance Spectroscopy (1) · Radiosurgery (1) · apalutamide (1) · enzalutamide (1) · gallium 68 PSMA-11 (1)
Barbara Ann Karmanos Cancer Institute (2) · Andrei Iagaru (1) · Jonsson Comprehensive Cancer Center (1) · OHSU Knight Cancer Institute (1) · University of California, San Francisco (1) · University of Washington (1)
United States (7)
Abhinav Deol, M.D. (1) · Andrei Iagaru (1) · Elisabeth I. Heath (1) · Heather H. Cheng (1) · Jeremie Calais (1) · Julie Graff, M.D. (1) · Rahul Aggarwal, MD (1)
PMID 32616555, PMID 33602654, PMID 37981040, PMID 38664016, PMID 39227508, PMID 41698328
P30CA022453 (2), P30CA015704 (1), P50CA097186 (1)